Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Short Interest Update

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,413,847 shares, an increase of 21.5% from the December 15th total of 1,986,266 shares. Currently, 4.3% of the company’s shares are short sold. Based on an average daily volume of 347,089 shares, the short-interest ratio is presently 7.0 days. Based on an average daily volume of 347,089 shares, the short-interest ratio is presently 7.0 days. Currently, 4.3% of the company’s shares are short sold.

Kestra Medical Technologies Stock Down 0.6%

Shares of KMTS stock traded down $0.13 on Monday, reaching $22.85. 298,820 shares of the company were exchanged, compared to its average volume of 243,751. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47. The company has a 50-day moving average of $25.63 and a 200-day moving average of $22.16. The company has a market cap of $1.33 billion and a price-to-earnings ratio of -7.21. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the completion of the sale, the insider owned 409,786 shares of the company’s stock, valued at approximately $10,896,209.74. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the completion of the transaction, the insider directly owned 136,633 shares in the company, valued at approximately $3,646,734.77. This represents a 7.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently modified their holdings of KMTS. China Universal Asset Management Co. Ltd. acquired a new position in shares of Kestra Medical Technologies during the third quarter worth approximately $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Kestra Medical Technologies during the second quarter worth $54,000. BNP Paribas Financial Markets raised its holdings in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares during the last quarter. Brown Brothers Harriman & Co. lifted its stake in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in shares of Kestra Medical Technologies during the second quarter valued at about $93,000.

Analysts Set New Price Targets

KMTS has been the topic of a number of recent analyst reports. Piper Sandler boosted their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Wells Fargo & Company increased their price target on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on Kestra Medical Technologies in a research report on Friday. Finally, Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.